New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
ENYO Pharma is proud to share the publication of the results from our Phase 2 LIVIFY study with Vonafexor in NASH patients in Journal of Hepatology.
This article describes the remarkable effects of Vonafexor after only 12 weeks of treatment in these patients: strong liver fat reduction, weight loss, liver enzyme improvements …., and last but not least renal function recovery. These strongly differentiated fibrolytic and anti-inflammatory effects of Vonafexor compared to other FXR agonists correlate very well with those observed in several preclinical models of severe CKD and rare kidney diseases like Alport Syndrome.
2022 International HBV Meeting
18-22 September, 2022
Paris, France.
ENYO Pharma sponsored and attent the 2022 International HBV Meeting on 18-22 September, 2022 organized by our collaborator Dr. David Durantel, Director of Research in Infectiology and team leader at the International Center for Research in Infectiology (CIRI-INSERM), Lyon, France.
https://www.hbvmeeting.org/
ASN Kidney Week
3-6 November 2022
Orlando, FL
ENYO Pharma was attending the world’s premier nephrology meeting of the American Society of Nephrology, ASN Kidney Week
https://www.asn-online.org/education/kidneyweek/
60th ERA congress, the Annual Nephrology Congress in Europe
15-18 June 2023
Milan, Italy
ENYO Pharma will attend and present at 60th ERA congress, the Annual Nephrology Congress in Europe
https://www.era-online.org/en/milan2023/
Multidisciplinary Day of Hepatology and Hepatic Transplantation
15 September, 2022
Lyon, France
ENYO Pharma sponsored and attent the Multidisciplinary Day of Hepatology and Hepatic Transplantation organized by Pr. Fabien Zoulim, Head of the Hepatology Department of the Hospices Civils de Lyon (HCL) the last September 15 at the Institute of Cognitive Sciences in Lyon, France. This annual seminar gathered around 150 professionals in hepatology.
Latest Press Release 